Affectis Pharmaceuticals AG Announces Target
Validation Collaboration with Organon

November 02, 2005 – News Release
Munich, Germany – Affectis Pharmaceuticals AG and Organon, the human healthcare business unit of Akzo Nobel, have entered into a collaboration by which Affectis will apply its pioneering target validation technology and its exclusive preclinical models for the validation of Organon’s gene targets involved in depression and anxiety. more...

Download German version

Affectis Pharmaceuticals AG Receives State Grants for the Development of Novel Antidepressants

October 18, 2005 – News Release
Munich, Germany – Affectis Pharmaceuticals AG today announced that it has received two research grants totalling € 2.2 million to broaden and progress its proprietary drug discovery and development programmes. more...

Download German version


Affectis Pharmaceuticals AG Closes € 4 Million Series B Investment

April 13, 2005 – News Release
Munich, Germany – Affectis Pharmaceuticals AG has closed a € 4 Million Series B second financing round led by EMBL Ventures, Heidelberg, Germany. Additional new investors participating in this financing round were DG Lux Multimanager I SICAV Lacuna APO BioTech, KfW, and Sunrise Water Ltd. Existing institutional investors LSP and BayernKapital as well as the Max-Planck-Society also participated. more...

Download German version
 
further News 2005